Literature DB >> 8037263

Amelioration of negative symptoms in schizophrenia by glycine.

D C Javitt1, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer.   

Abstract

Phencyclidine induces a psychotomimetic state by blocking neurotransmission at N-methyl-D-aspartic acid (NMDA) receptors. In a double-blind, placebo-controlled fashion, 14 medicated patients with chronic schizophrenia were treated with glycine, a potentiator of NMDA-receptor-mediated neurotransmission. Significant improvement in negative symptoms occurred in the group given glycine but not in the group given placebo, suggesting that potentiation of NMDA-receptor-mediated neurotransmission may represent an effective treatment for neuroleptic-resistant negative symptoms in schizophrenia.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8037263     DOI： 10.1176/ajp.151.8.1234

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  65 in total

1.  New style clinical trials in schizophrenia.

Authors:  W T Carpenter
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 4.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

5.  Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice.

Authors:  Manavi Chatterjee; Seema Singh; Reena Kumari; Anil Kumar Verma; Gautam Palit
Journal:  Neurochem Res       Date:  2011-12-22       Impact factor: 3.996

6.  Different effects of α- and γ-polymorphs of glycine on behavior of GC rats predisposed to catalepsy.

Authors:  A L Markel; A F Achkasov; O I Prokudina; T A Alekhina; E V Boldyreva; V V Boldyrev
Journal:  Dokl Biochem Biophys       Date:  2010-10-20       Impact factor: 0.788

Review 7.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

8.  Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Authors:  Katalin Nagy; Bernadett Marko; Gabriella Zsilla; Peter Matyus; Katalin Pallagi; Geza Szabo; Zsolt Juranyi; Jozsef Barkoczy; Gyorgy Levay; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 9.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

10.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.